Tiotropium assessments in two hundred and fifty-two COPD patients

A. Woolley, S. A. Collis, T. Shaw (Southampton, Bournemouth, United Kingdom)

Source: Annual Congress 2008 - Organisation of care and management of COPD
Session: Organisation of care and management of COPD
Session type: Thematic Poster Session
Number: 3320
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Woolley, S. A. Collis, T. Shaw (Southampton, Bournemouth, United Kingdom). Tiotropium assessments in two hundred and fifty-two COPD patients. Eur Respir J 2008; 32: Suppl. 52, 3320

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Tiotropium in COPD patients
Source: Breathe 2008; 5: 271
Year: 2009

Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006

Care-continuity for COPD patients
Source: Annual Congress 2012 - Nursing led education and follow-up strategies: impact on readmission, self care and patient experiences
Year: 2012


COPD patients
Source: Eur Respir Monogr 2021; 90: 154-164
Year: 2021


Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Neutrophils and spirometry changes in COPD patients treated with roflumilast
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015

Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Once-daily QVA149 improves symptom scores in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Spirometry quality in patients with COPD
Source: Annual Congress 2011 - Quality control in lung function and exercise-related issues
Year: 2011


Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Bronchodilator efficacy of tiotropium in patients with mild COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

How the bronchodilatator in COPD patients works
Source: Eur Respir J 2004; 24: Suppl. 48, 288s
Year: 2004

Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001

QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015